SUNNYVALE, Calif., Oct. 28, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) – Thailand's Lopburi Cancer Hospital, a center
of excellence for cancer treatment, is the first in the
Asia-Pacific region to clinically
use the combination of RaySearch's treatment planning system
RayStation® with Accuray's Radixact® Treatment Delivery System.
Lopburi has a focus on innovation and has been designated a
national center of excellence for cancer treatment. Today it
provides specialist treatment to patients in twelve provinces
around the country. The hospital selected RayStation as its
treatment planning system in 2015, largely due to the system's
automated breast planning capabilities and unique multi-criteria
optimization. Since its implementation, RayStation has enhanced the
clinic's workflows, reduced calculation times and ensured
consistently high-quality treatment plans.
The Lopburi team, led by Dr. Kriengkri Namthaisong, hospital
director and Mr. Somsak Khaunchana, head of medical physics,
recently installed the Radixact System, an innovative radiation
therapy device that combines integrated CT imaging with a unique
helical delivery platform enabling the delivery of radiation from
360 degrees around the patient. It can target a wide range of
tumors, including those in the abdomen, brain, breast, lung and
head & neck. Treatment accuracy and precision are achieved
through daily 3D image guidance that helps ensure proper patient
positioning and accurate dose delivery to the target even when
anatomical changes occur.
Sutthisak Kulpisitthicharoen, M.D., radiation oncologist at
Lopburi Cancer Hospital, says: "RayStation is easy to use and
enables highly accurate treatment planning. We appreciate the
multi-criteria optimization functionality, which is fast and gives
the planner many possibilities. Contouring is precise and
convenient, and the fallback planning feature means we can transfer
treatment to an alternative machine if needed, without the need to
re-plan. RayStation and Radixact are highly innovative systems, and
the combination is excellent, particularly for complex cases."
Chonthon Phihuasuth, medical physicist at Lopburi Cancer
Hospital, says: "Using RayStation and Radixact together improves
treatment accuracy. The synergies between these innovations will
reduce time both in treatment planning and treatment delivery, as
well as increase efficiency. Radixact planning in RayStation
enables us to achieve highly conformal dose distributions with
lower doses to organs at risk, resulting in effective treatment
with fewer complications for patients."
Johan Löf, founder and CEO of RaySearch, says: "Lopburi Cancer
Hospital is a forward-looking center with a commitment to improve
care through the latest technology. We are very pleased to support
their planning needs for Accuray's advanced Radixact System. The
synergies between the two systems bring great benefits for
patients, as well as improving workflow efficiency for the
clinic."
Joshua H. Levine, president and
CEO at Accuray, says: "The Lopburi Cancer Hospital is raising the
bar for other centers providing radiation therapy treatments. The
clinical team's decision to treat cancer patients using the
combination of RayStation and Radixact will expand access to
state-of-the-art cancer treatment technologies for the people of
Thailand. Together, RayStation and
Radixact provide capabilities that align well with the hospital's
goal of delivering the most effective treatments possible."
About Lopburi Cancer Hospital
Lopburi Cancer Hospital is a leading facility in the Mueang
district of Thailand and has been
designated a national center of excellence. The center is a pioneer
of advanced technology and treats patients from provinces around
the country using techniques such as TomoTherapy® as well as
conventional radiation therapy.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Accuray Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
experiences and results, patient experiences and outcomes, and the
expansion of access to cancer treatment technologies in
Thailand. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of Accuray's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to,
the risks identified under the heading "Risk Factors" in the
Accuray 's annual report on Form 10-K, filed with
the Securities and Exchange Commission (the "SEC")
on August 23, 2019, and as updated periodically with Accuray
's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or Accuray
management's good faith belief as of that time with respect to
future events. Accuray assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
About RaySearch
RaySearch is a medical technology company that develops innovative
software solutions to improve cancer care. The company markets the
RayStation treatment planning system and RayCare®*, the
next-generation oncology information system, worldwide. Over 2,600
clinics in more than 65 countries use RaySearch software to improve
life and outcomes for patients. The company was founded in 2000 and
the share has been listed on Nasdaq Stockholm since 2003.
About RayStation
RayStation is a flexible, innovative treatment planning system,
chosen by many of the leading cancer centers worldwide. It combines
unique features such as unmatched adaptive therapy capabilities,
multi-criteria optimization, market-leading algorithms for IMRT and
VMAT optimization with highly accurate dose engines for photon,
electron, proton and carbon ion therapy. RayStation supports a wide
range of treatment machines, providing one control center for all
treatment planning needs and ensuring centers get greater value
from existing equipment. RayStation also seamlessly integrates with
RayCare, the next-generation oncology information system. By
harmonizing the treatment planning, we enable better care for
cancer patients worldwide. More information about RaySearch is
available at www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
RaySearch:
Johan Löf, Founder and CEO, RaySearch
Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com
Peter Thysell, CFO, RaySearch
Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com
Accuray:
Beth Kaplan,
Public Relations Director, Accuray
Telephone: +1 (408)
789-4426
bkaplan@accuray.com
Jayme Maniatis, MSLGROUP
Telephone: +1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/first-asia-pacific-hospital-treats-patients-with-raystation-and-radixact-300945887.html
SOURCE Accuray Incorporated